Valby, Denmark

Lars Christian Biilmann Rønn

USPTO Granted Patents = 6 

 

Average Co-Inventor Count = 9.0

ph-index = 2

Forward Citations = 13(Granted Patents)


Company Filing History:


Years Active: 2019-2025

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: The Innovations of Lars Christian Biilmann Rønn

Introduction

Lars Christian Biilmann Rønn is a notable inventor based in Valby, Denmark. He has made significant contributions to the field of medical treatments, particularly through his innovative patents. With a total of six patents to his name, Rønn has focused on developing solutions for serious health conditions.

Latest Patents

Among his latest patents, Rønn has developed monoclonal anti-Sortilin antibodies. These antibodies are particularly useful in correcting a deficient level of progranulin (PGRN). His inventions have shown promise in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The dual focus on these critical health issues highlights the importance of his work in the medical field.

Career Highlights

Rønn is currently associated with H. Lundbeck A/S, a company known for its dedication to improving the lives of people with brain diseases. His role at Lundbeck allows him to leverage his expertise in developing innovative treatments that address unmet medical needs. His contributions have been instrumental in advancing research and development in the pharmaceutical industry.

Collaborations

Rønn has collaborated with notable colleagues such as Ibrahim John Malik and Jeffrey B Stavenhagen. These partnerships have enhanced the scope and impact of his research, leading to significant advancements in the treatment of neurological disorders.

Conclusion

Lars Christian Biilmann Rønn's work exemplifies the spirit of innovation in the medical field. His patents and collaborations reflect a commitment to addressing critical health challenges. Through his efforts, Rønn continues to make a meaningful impact on the lives of patients suffering from serious conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…